Showing results (1-10 of 606) with videos related to
Sort By:
Pageof 61
The Annals of Pharmacotherapy|May 30, 2003
Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance ProgramAlan H Mutnick, Victoria Enne, Ronald N JonesThe Annals of Pharmacotherapy|December 31, 2002
CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging ResistanceAlan H Mutnick, Jeffrey T Kirby, Ronald N Jones, et al.Journal of Clinical Microbiology|November 1, 2002
Impact of modified nonmeningeal Streptococcus pneumoniae interpretive criteria (NCCLS M100-S12) on the susceptibility patterns of five parenteral cephalosporins: report from the SENTRY antimicrobial surveillance program (1997 to 2001)Ronald N Jones, Alan H Mutnick, David J VarnamDiagnostic Microbiology and Infectious Disease|May 6, 2003
Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000)Robert P Rennie, Ronald N Jones, Alan H Mutnick, et al.Diagnostic Microbiology and Infectious Disease|May 14, 2003
Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997-2000)Alan H Mutnick, Douglas J Biedenbach, Ronald N JonesThe Journal of Antimicrobial Chemotherapy|December 4, 2002
In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococciRonald N Jones, Lalitagauri M Deshpande, Alan H Mutnick, et al.Diagnostic Microbiology and Infectious Disease|May 6, 2003
Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000)Daryl J Hoban, Douglas J Biedenbach, Alan H Mutnick, et al.Diagnostic Microbiology and Infectious Disease|June 8, 2002
Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000Alan H Mutnick, Douglas J Biedenbach, John D Turnidge, et al.Diagnostic Microbiology and Infectious Disease|November 5, 2003
Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002)Helio S Sader, Thomas R Fritsche, Alan H Mutnick, et al.The Journal of Antimicrobial Chemotherapy|January 9, 2004
Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001)Alan H Mutnick, Paul R Rhomberg, Helio S Sader, et al.Pageof 61